ClinicalTrials.gg
DrugRead study by study

Inavolisib clinical trials

Also written GDC-0077, RO7113755 and Itovebi.

studies test it
32
open now
21
in phase 3
5
first study started
2016
ClinicalTrials.gov finds 37 studies for inavolisib. How that becomes 32 here

Every study that search finds has been read, to see whether and how it gives inavolisib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count

  1. 37Found by its intervention search · See all 37 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 34 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −1
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 36Give inavolisib to participants
  4. −3Observe patients on it, or give it outside a trial
  5. −1Give it beside what is tested
  6. 32Test it: the count on this site

Get an email when these change. Save the inavolisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 Oct 2024 · ITOVEBI · NDA 219249 (FDA, Drugs@FDA)
European Union
18 Jul 2025 · Itovebi · EMEA/H/C/006353 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Inavolisib
27

Brand

Itovebi
3

Development codes

GDC-0077
11
RO7113755
5
RG6114
2

Studies by the year they started

32 studies that test it; most in 2026 (10)

Studies that test inavolisib, by start year
YearStudies
20161
20181
20201
20218
20236
20241
20254
202610

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
23
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 12

Hoffmann-La Roche (17) · Genentech, Inc. (3) · German Cancer Research Center (2) · MedSIR (1) · Women's Hospital School Of Medicine Zhejiang University (1) · Fudan University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · National Cancer Institute, Naples (1)

Often tested with

Tested in the same studies.

Ipatasertib (8) · Atezolizumab (7) · Giredestrant (5) · Ado-Trastuzumab Emtansine (4) · Bevacizumab (4) · Tiragolumab (4) · Paclitaxel (3) · Alectinib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 1 most studied

New when their studies opened, with inavolisib beside them; studies of each.

Reaching primary completion within a year · 8, 2 in phase 3

Studies that test inavolisib, phase 3 first.

Studies

Open first, then newest update. How each study uses inavolisib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 32

See all 32 studies that test inavolisib →

Behind its US label · 1 — the studies the FDA label of ITOVEBI describes

From the Clinical Studies section of ITOVEBI (2026-04), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 4 — no other medicine in its arm
Tested with established drugs · 12 — they are given beside it
Tested in a combination · 16 — another drug in the study is under test too
Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with inavolisib: divarasib 1

Observed · 3 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 17, 2026.

Codes

What other systems call inavolisib · ClinicalTrials.gg INT001966

  • MeSH (NLM) C000723546inavolisibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) L4C1UY2NYHINAVOLISIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q76855355inavolisibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C132166InavolisibOne source FDA
  • DrugBank DB15275One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion